Blood test to detect ATTR amyloidosis earlier using a smart detection kit
Official title: Development of a blood-based diagnostic test for ATTR amyloidosis
Funded at Amygo Solutions LLC · NIH-11407018 · Data updated 2026-11-12
A new blood test kit aims to detect ATTR amyloidosis early using a biomarker that appears in patients but not in healthy people.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amygo Solutions LLC NIH-funded |
| Lab location | 1 site (Grand Prairie, United States) |
| Project start | September 5, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $329,469 |
| NIH project number | 1R43HL186878-01 |
| Project ID | NIH-11407018 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults suspected of having ATTR amyloidosis or at risk due to symptoms or family history.
✕Less likely to help
Patients without ATTR amyloidosis or those unlikely to benefit from early detection may not experience direct gains.
What this research studies
This project focuses on creating and validating a simple, automated blood test that can be used in standard clinical labs to screen for transthyretin amyloidosis. It uses a proprietary marker to identify misfolded TTR aggregates, potentially enabling earlier diagnosis and faster treatment decisions. The effort includes making the test kit-friendly and compatible with routine workflows to reduce costs and reliance on specialized techniques. If successful, clinicians could detect ATTR earlier and start therapies sooner, potentially improving patient outcomes.
Why it matters
Potential benefit: If successful, patients could be diagnosed earlier through a convenient blood test, enabling timely treatment.
How similar studies have gone: This approach builds on a validated biomarker concept and SBIR groundwork, with prior steps showing promise in detecting pathogenic TTR aggregates.
Where this research is happening
-
Amygo Solutions LLC
Grand Prairie, United States Active
Researchers
- Principal investigator: Pedretti, Rose — Amygo Solutions LLC
- Study coordinator: Pedretti, Rose
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney-like blood flow may cause amyloid buildup
A research project uses tiny blood-flow devices to study how certain proteins misfold and form amyloid deposits in organs like the kidney and heart.
-
Detection and measurement of amyloid in people carrying the V122I TTR gene variant
This research will look for early signs of heart-related amyloidosis in people with the V122I TTR gene variant using blood tests and a special imaging scan.
-
Identifying Hidden Cardiac Amyloidosis in Black V122I TTR Carriers
This project looks for early signs of heart damage in Black individuals who carry the V122I TTR variant and may benefit from new treatments if caught early.
-
Chip phosphorylation boosts breakdown of mutant TTR to help heart amyloidosis
A scientist-led project aims to help people with a heart disease caused by a mutant protein called transthyretin (TTR) by boosting the body’s protein-cleanup systems to remove the harmful TTR deposits.
-
Finding transthyretin heart amyloid from lumbar spine surgery tissue
This project looks for transthyretin (TTR) amyloid in tissue removed during lumbar spine surgery to find people who may later develop TTR cardiac amyloidosis.
-
Blood biomarker test for heart amyloidosis in Black and Hispanic people
A blood test called TAD1 is being checked to detect dangerous heart amyloidosis earlier in Black and Hispanic patients who have heart failure.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.